PFE

Bristol Myers Squibb demonstrates steadier year-over-year revenue growth with consistent upward trends, while Pfizer shows higher absolute revenue but experienced recent fluctuations and contraction periods. BMY's revenue is projected to edge up 3% to $49.9 billion with net income rising over 40%, while PFE's revenue is expected to slump slightly to $62.2 billion despite net income gains. Based on revenue trends alone, Bristol Myers Squibb appears to be on a better trajectory, though both companies show positive comparable quarter-over-quarter growth.

Pfizer (PFE) closed at $30.11, up 2.28%, outperforming the S&P 500. The stock has gained 6.13% over the past month.

However, the company faces headwinds with expected Q3 2026 EPS declining 17.24% year-over-year and full-year earnings projected down 8.39%. Pfizer holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 9.99, trading at a discount to its industry average. The Large Cap Pharmaceuticals industry ranks in the bottom 12% of sectors.

Pfizer has been trending on Zacks.com with shares returning +6.1% over the past month, outperforming the S&P 500's +0.7% gain. However, the company faces headwinds with earnings expected to decline 8.4% year-over-year for the current fiscal year and revenue projected to remain flat. Despite beating consensus estimates in recent quarters and trading at a discount to peers, Pfizer received a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market in the near term.